Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Payables (2021 - 2026)

bioAffinity Technologies has reported Payables over the past 6 years, most recently at $897352.0 for Q1 2026.

  • Quarterly Payables fell 39.63% to $897352.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $897352.0 through Mar 2026, down 39.63% year-over-year, with the annual reading at $867062.0 for FY2025, 25.19% down from the prior year.
  • Payables was $897352.0 for Q1 2026 at bioAffinity Technologies, up from $867062.0 in the prior quarter.
  • Over five years, Payables peaked at $1.5 million in Q1 2025 and troughed at $146537.0 in Q1 2023.
  • The 5-year median for Payables is $852208.0 (2024), against an average of $770241.9.
  • Year-over-year, Payables tumbled 96.97% in 2022 and then soared 388.64% in 2024.
  • A 5-year view of Payables shows it stood at $345042.0 in 2022, then soared by 75.28% to $604789.0 in 2023, then surged by 91.63% to $1.2 million in 2024, then fell by 25.19% to $867062.0 in 2025, then rose by 3.49% to $897352.0 in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Payables are $897352.0 (Q1 2026), $867062.0 (Q4 2025), and $1.1 million (Q3 2025).